Truist analyst Richard Newitter raised the firm’s price target on Boston Scientific (BSX) to $120 from $110 and keeps a Buy rating on the ...

Citi raised the firm’s price target on Boston Scientific (BSX) to $122 from $107 and keeps a Buy rating on the shares. The company reported ...

Continuing its acquisition streak into 2025, Marlborough-based medical device manufacturer Boston Scientific has entered into a definitive agreement to acquire California-based medical equipment ...

Plans to buy Bolt Medical, Inc., a developer of intravascular lithotripsy equipment for treating hardened coronary and peripheral artery disease, were announced by Boston Scientific Corporation ...

But there’s a powerful fundamental story happening with Boston Scientific. Also, EPS is estimated to ramp higher this year by +13.8%. Now it makes sense why the stock has been powering to new ...

Boston Scientific Corporation today announced it has entered into a definitive agreement to acquire Bolt Medical, Inc., the developer of an intravascular lithotripsy (IVL) advanced laser-based ...

The Marlborough device maker is paying $443 million upfront, plus up to $221 million in possible milestones, to buy the remainder of a company in which it already owned a major stake. Boston ...

I’m still a believer in the story at Boston Scientific, but the valuation situation remains challenging. I do think there’s a credible chance of BSX generating 10% long-term revenue growth and ...

Boston Scientific is diving into the field of intravascular lithotripsy, with a $664 million deal to pick up Bolt Medical and its hardware for breaking through hardened and clogged arteries.

Liquid biopsy is one of them. A traditional biopsy usually involves taking a tiny tissue sample from the body to diagnose a disease and to understand the extent of its progression. But liquid ...